Extended ganciclovir prophylaxis in lung transplantation

Area of Science:

• Transplantation immunology
• Infectious disease management

Background:

• Cytomegalovirus (CMV) infection in donor or recipient negatively impacts lung transplant survival and increases bronchiolitis obliterans syndrome (BOS) risk.
• The efficacy of ganciclovir prophylaxis against CMV infection in relation to BOS development remains unclear.

Purpose of the Study:

• To evaluate the impact of varying ganciclovir prophylaxis durations on cytomegaloviral disease, rejection episodes, BOS development, and survival in lung transplant recipients.

Main Methods:

• Retrospective analysis of 146 lung transplant recipients from a single center, categorized by ganciclovir prophylaxis: none (Group 1), 4 weeks IV (Group 2), and 3 months IV/oral (Group 3).
• Comparison of outcomes including cytomegaloviral disease, rejection episodes, time to BOS, and survival, adjusting for transplant type and HLA typing.

Main Results:

• Significant reduction in cytomegaloviral disease episodes in the first post-transplant year with increasing ganciclovir prophylaxis duration.
• A decrease in rejection episodes was observed from Group 1 to Group 3.
• No statistically significant difference in time to BOS occurrence or actuarial survival was found across the groups.

Conclusions:

• Extended ganciclovir prophylaxis effectively prevents cytomegaloviral disease and reduces rejection episodes post-lung transplantation.
• Ganciclovir prophylaxis, regardless of duration, did not demonstrate a significant benefit in preventing BOS or improving long-term survival.